Search the Newsreel

Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans

Inhibikase Therapeutics announced that its lead product candidate, IKT-001, has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Pulmonary Arterial Hypertension (PAH), a condition affecting approximately 50,000 Americans. This designation provides incentives such as tax credits, exemption from FDA …

Militia Capital Management LLC Makes New $2.46 Million Investment in National Health Investors, Inc. $NHI

Militia Capital Management LLC has made a new investment of $2.46 million in National Health Investors, Inc. (NYSE:NHI) by acquiring 30,400 shares in the first quarter. This makes Militia Capital Management LLC own about 0.06% of the company's stock. Other institutional investors also adjusted …

Companhia Siderurgica Nacional: The Deleveraging Thesis Has Turned Into A Value Trap (SID)

NHI stock trades below recent highs as healthcare REIT focuses on portfolio transitions

National Health Investors (NHI) stock is trading below recent highs as the healthcare REIT undergoes a portfolio reshaping, focusing on senior housing communities despite facing pressure on rental income in 2023. The company reported a modest revenue decline and slightly lower FFO, but has …

Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

Inhibrx Biosciences expanded its credit facility to $500.0 million with Oxford Finance, including an immediate $100.0 million Term C Loan. This move reduces short-term financing pressure and offers management more flexibility for trials, but also introduces higher leverage and financial risk. The company's investment …

National Steel (NYSE:SID) Trading 6.5% Higher - What's Next?

Zacks.com featured highlights include Invesco Aveanna Healthcare, Companhia Paranaense de Energia - COPEL and ArcBest

For Immediate Release Chicago, IL – July 21, 2026 – Stocks in this week's article are Invesco Ltd. IVZ, Aveanna Healthcare AVAH, Companhia Paranaense de Energia ELPC - COPEL and ArcBest ARCB. 4 Discounted PEG Value Picks Following the June CPI Inflation Report The …

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details of the merger or …

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indicating a lack of activity …

National Health Investors, Inc. (NYSE:NHI) Receives Average Rating of "Moderate Buy" from Analysts

MarketBeat reports that National Health Investors, Inc. (NYSE:NHI) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month target price of $83.8571. Recent analyst reports show mixed recommendations, including downgrades and price target adjustments. Insider buying activity by the company's director …

(NHI) Risk Channels and Responsive Allocation

This article from Stock Traders Daily provides an AI-generated analysis for National Health Investors Inc. (NYSE: NHI), highlighting strong near-term sentiment with neutral mid and long-term outlooks. It details specific trading strategies including Position, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis …

ELPC Q2 2025 Earnings: Strong Earnings Beat Drives Positive Stock Reaction - Upward Estimate Revision

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was July 10, 2026, with …

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage biotech focused …

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these newly …

NHI6183473 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the National Health Investors, Inc. bond NHI6183473, detailing its interest rate and payment schedule. The bond has a current coupon rate of 5.35%, with the next payment anticipated on August 3, 2026. It encourages users to unlock …

NHI stock holds as National Health Investors reports steady rent coverage

National Health Investors (NHI) stock remains stable, driven by reported rent coverage and a consistent dividend track record. The company, a REIT focusing on healthcare properties like senior housing and assisted living, emphasizes recurring rental cash flow and portfolio stability as key investment metrics. …

NHI6183473 Bond Profile — Key Metrics

This article provides key metrics for the National Health Investors, Inc. (NHI) bond, NHI6183473, which has a 5.35% coupon and matures on February 1, 2033. The bond has an outstanding amount of $350 million and a face value of $1,000. It also outlines National …

Copel Updates Dividend Policy to Tighten Payout Rules and Leverage Targets

Copel has updated its dividend policy to enhance transparency and predictability in shareholder payouts. The new policy targets distributing at least 75% of adjusted net profit annually and sets a leverage limit of 2.9x Net Debt/EBITDA. These changes are designed to balance investor compensation …

Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional …

Short Interest in Companhia Paranaense de Energia - Copel Unsponsored ADR (NYSE:ELPC) Decreases By 37.4%

Wells Fargo Remains a Hold on National Health Investors (NHI)

Wells Fargo analyst John Kilichowski maintained a Hold rating on National Health Investors (NHI) with a price target of $89.00. The company reported strong quarterly revenues and net profits, and corporate insider sentiment is positive with recent insider share purchases. The analyst consensus on …

Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit

Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an …

Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants

Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collateral. These …

Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its drug candidates. The agreement also adjusts …

National Health Investors, Inc. $NHI Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in National Health Investors (NYSE:NHI) by 2.0% in the first quarter, now owning over 1.7 million shares. Several other institutional investors also adjusted their positions, and insiders Robert A. Mccabe, Jr. and D. Eric Mendelsohn recently purchased …

NHI to release Q2FY26 earnings on August 10, 2026

National Health Investors, Inc. (NHI) announced it will release its second-quarter financial results for FY26 on August 10, 2026, after market close. A conference call is scheduled for August 11, 2026, at 8:30 a.m. ET to discuss the performance, with dial-in and webcast details …

Wells Fargo Maintains National Health Investors Inc(NHI.US) With Hold Rating, Raises Target Price to $89

Wells Fargo has reaffirmed its Hold rating for National Health Investors Inc (NHI.US). The firm also increased its price target for NHI to $89, indicating a revised outlook for the company's stock performance.

National Health Investors Sets Aug. 11 Q2 Results Call

National Health Investors (NYSE: NHI) has scheduled its second quarter 2026 earnings release and conference call. The company will release its financial results on Monday, August 10, 2026, after market close, and host a conference call the following day, August 11, 2026, at 8:30 …

NHI Announces Second Quarter 2026 Earnings Release and Conference Call Dates

National Health Investors, Inc. (NHI) has announced that it will release its second quarter 2026 earnings after the market closes on Monday, August 10, 2026. A conference call to discuss these results will follow on Tuesday, August 11, 2026, at 8:30 a.m. Eastern Time. …

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn Continues - Share Repurchase Impact

Previsão AGRO3 — Preço Alvo para 2027

Previsão CPLE3 — Preço Alvo para 2027

Previsão PCAR3 — Preço Alvo para 2027

Previsão SAPR4 — Preço Alvo para 2027

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)